Adebellizumab
Phase 2Monoclonal antibody
Adebellizumab is one of 90 small molecule programs targeting Neoadjuvant Therapy. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
89
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Medrol
PfizerPreclinical
Adebellizumab
ZZhejiang University
Phase 2
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Sulfonylureas
Eli LillyPreclinical
Active Comparator
ModernaPreclinical
Cyclophosphamid
EEssen Biotech
Preclinical
PEG-Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adebellizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang University